Clinical trial · Observational
Cohort Study for Gastric MALT Lymphoma
Establishment of a Cohort for Investigating the Pathophysiology of Gastric MALT Lymphoma
NCT06454149CI-TRIAL-00077887HUG-MALTomarecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260929-000001
Summary
Brief summary (as posted)
The goal of this observational study is to establish clinical data and tissue repository in patients with gastric MALT lymphoma and controls. Participants will be asked to provide clinical information and various tissues (saliva, gastric mucosa, and feces).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric MALT Lymphoma | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MALT lymphoma | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- MALT lymphoma
- description
- Patients who were newly diagnosed as gastric MALT lymphoma
- interventionNames
- Other: MALT lymphoma
- label
- Control group
- description
- Patients who underwent 1. diagnosed upper endoscopy for dyspepsia and had chronic gastritis, 2. therapeutic upper endoscopy for gastric hyperplastic polyps, or 3. screening upper endoscopy without any symptoms.
Primary outcomes (1)
- measure
- Remission of gastric MALT lymphoma
- timeFrame
- Within 3 years from diagnosis
- description
- Remission of gastric MALT lymphoma
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: \[MALT lymphoma group\] * Newly diagnosed as gastric MALT lymphoma \[Control group\] * Patients who underwent 1. diagnosed upper endoscopy for dyspepsia and had chronic gastritis, 2. therapeutic upper endoscopy for gastric hyperplastic polyps, or 3. screening upper endoscopy without any symptoms. Exclusion Criteria: * History of gastric or other malignancy * Use of antibiotics or probiotics within 4 weeks * Uncontrolled chronic illnesses
References
Publications (4)
- BACKGROUNDZucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jan;31(1):17-29. doi: 10.1016/j.annonc.2019.10.010. Epub 2019 Dec 4. No abstract available. PMID 31912792
- BACKGROUNDDi Rocco A, Petrucci L, Assanto GM, Martelli M, Pulsoni A. Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment. Cancers (Basel). 2022 Mar 29;14(7):1742. doi: 10.3390/cancers14071742. PMID 35406516
- BACKGROUNDTanaka T, Matsuno Y, Torisu T, Shibata H, Hirano A, Umeno J, Kawasaki K, Fujioka S, Fuyuno Y, Moriyama T, Esaki M, Kitazono T. Gastric microbiota in patients with Helicobacter pylori-negative gastric MALT lymphoma. Medicine (Baltimore). 2021 Sep 24;100(38):e27287. doi: 10.1097/MD.0000000000027287. PMID 34559138
- BACKGROUNDLemos FFB, Silva Luz M, Rocha Pinheiro SL, Teixeira KN, Freire de Melo F. Role of non-Helicobacter pylori gastric Helicobacters in helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol. 2023 Aug 28;29(32):4851-4859. doi: 10.3748/wjg.v29.i32.4851. PMID 37701138